Title
Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA
Date Issued
01 August 2008
Access level
metadata only access
Resource Type
journal article
Author(s)
Livorsi D.
Daver N.
Atmar R.
Shelburne S.
Musher D.
University of Texas Medical Branch
Publisher(s)
Elsevier
Abstract
Objectives: Hematogenous vertebral osteomyelitis is caused predominantly by Staphylococcus aureus. The rise in incidence of methicillin-resistant S. aureus (MRSA) has complicated the treatment of this infection. Our objective was to evaluate therapeutic outcomes for S. aureus vertebral osteomyelitis in a setting of high MRSA prevalence. Methods: We conducted a retrospective chart review of all patients who presented with S. aureus vertebral osteomyelitis over a 7-year period at 2 tertiary care hospitals in Houston, TX, USA. Results: Thirty-five patients were identified who received ≥2-week course of parenteral antibiotics and had a follow-up period of at least 12 months post-therapy. MRSA was responsible for 20 (57%) cases. Mean duration of total antibiotic therapy was 61.4 days. The overall relapse rate was 14%. At 12 months post-therapy, 86% patients were cured. The one factor significantly associated with relapse was presence of undrained abscesses (p = 0.04). Conclusions: When the mean duration of effective antibiotic therapy was 60 days, cure rates for S. aureus vertebral osteomyelitis exceeded 80%. Drainage of all associated abscesses correlated with a significantly higher rate of cure. © 2008 The British Infection Society.
Start page
128
End page
131
Volume
57
Issue
2
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Scopus EID
2-s2.0-48449095737
PubMed ID
Source
Journal of Infection
ISSN of the container
0163-4453
Sponsor(s)
National Cancer Institute P30CA016672 NCI
Sources of information: Directorio de Producción Científica Scopus